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Abstract
Primary progressive aphasia (PPA) is a neurodegenerative disorder with language impairment as the primary feature. Different subtypes
have been described and the 3 best characterized are progressive nonfluent aphasia (PNFA), semantic dementia (SD) and logopenic/
phonological aphasia (LPA). Of these subtypes, LPA is most commonly associated with Alzheimer’s disease (AD) pathology. However, the
features of PPA associated with AD have not been fully defined. Here we retrospectively identified 14 patients with PPA and either
pathologically confirmed AD or cerebrospinal fluid (CSF) biomarkers consistent with AD. Analysis of neurological and neuropsychological
features revealed that all patients had a syndrome of LPA with relatively nonfluent spontaneous speech, phonemic errors, and reduced digit
span; most patients also had impaired verbal episodic memory. Analysis of the pattern of cortical thinning in these patients revealed left
posterior superior temporal, inferior parietal, medial temporal, and posterior cingulate involvement and in patients with more severe disease,
increasing involvement of left anterior temporal and frontal cortices and right hemisphere areas in the temporo-parietal junction, posterior
cingulate, and medial temporal lobe. We propose that LPA may be a “unihemispheric” presentation of AD, and discuss this concept in
relation to accumulating evidence concerning language dysfunction in AD.
© 2012 Elsevier Inc.
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Primary progressive aphasia (PPA) refers to a group of
neurodegenerative disorders with language impairment as
the initial symptom (Mesulam, 1982, 2001, 2003). These
disorders are of high neurobiological and clinical impor-
tance because they illustrate the potentially focal nature of
neurodegenerative disease and the potential heterogeneity
of clinical presentations even where the underlying patho-
logical process is uniform. The best characterized subtypes
of PPA are progressive nonfluent aphasia (PNFA) and se-
mantic dementia (SD). Patients with PNFA have nonfluent
speech characterized by agrammatism and/or a motor
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Open access under CC BY license.speech impairment (usually an apraxia of speech, i.e., hes-
itancy and effortfulness attributable to impaired planning of
articulation) (Ogar et al., 2007). SD presents with fluent
aphasia, anomia, and single word comprehension deficits
secondary to verbal semantic impairment (Hodges and Pat-
terson, 2007). “Fluency” in this context refers to the flow of
speech. However, dysfluency may arise from a variety of
underlying deficits, including agrammatism, impaired artic-
ulation (motor deficits such as apraxia of speech), decreased
phrase length or slower speech rate (e.g., due to word-
finding pauses); patients referred to as having a “nonfluent
aphasia” may have various more or less distinct primary
language or speech impairments. This theme is well illus-
trated by the recently recognized entity of logopenic/pho-
nological aphasia (LPA) (Gorno-Tempini et al., 2004,
2008), which constitutes a third major syndrome within the
PPA spectrum. Patients with LPA have word-finding pauses
and anomia as well as impaired speech repetition, particu-
larly sentences (Gorno-Tempini et al., 2008).
745J.D. Rohrer et al. / Neurobiology of Aging 33 (2012) 744–752Most cases of PPA have a non-Alzheimer pathological
substrate within the frontotemporal lobar degeneration spec-
trum, and are usually associated predominantly with either
tau- or TAR (trans-activation-response) DNA binding pro-
tein 43 (TDP-43)-positive cellular inclusions (known as
FTLD-tau or FTLD-TDP pathology), respectively (Knibb et
al., 2006; Snowden et al., 2007). However, it has long been
recognized that PPA syndromes may also be associated with
Alzheimer’s disease (AD) pathology (Clark et al., 2003;
Green et al., 1990, 1996; Karbe et al., 1993; Kempler et al.,
1990; Li et al., 2000; Pogacar and Williams, 1984) and in
recent years more detailed series have been reported (Alladi
et al., 2007; Croot et al., 2000; Davies et al., 2005; Galton
et al., 2000; Josephs et al., 2008; Kertesz et al., 2005; Knibb
et al., 2006; Mesulam et al., 2008). In particular, recent
evidence has suggested that LPA is underpinned by AD
pathology in a high proportion of cases and may be the most
common aphasia phenotype of AD (Gorno-Tempini et al.,
2008; Mesulam et al., 2008; Rabinovici et al., 2008). How-
ever both PNFA and SD have also been reported with AD
pathology, as have syndromes that do not fit clearly into a
single category, so-called “mixed” aphasia (Alladi et al.,
2007; Knibb et al., 2006). As AD is the most common
neurodegenerative disease of later life, the range of pheno-
typic variation in AD and the mechanisms that drive this
variation are key issues in the field of neurodegenerative
disease.
Here we review the clinical, neuropsychological and
cross-sectional neuroimaging features of a retrospective se-
ries of patients with a clinical diagnosis of PPA and AD
pathology either demonstrated directly or presumed on the
basis of cerebrospinal fluid (CSF) biomarker profiles. We
consider these cases in relation to previously published
series of PPA patients with either pathologically confirmed
AD or a positive Pittsburgh compound B (PIB)-positron
emission tomography (PET) scan suggestive of AD.
2. Methods
From the Dementia Research Centre patient database
comprising a consecutive series of patients seen between
1992 and 2008, we extracted all cases meeting criteria for
PPA (Mesulam, 2001, 2003) and who had either AD pa-
thology at postmortem/cerebral biopsy or CSF biomarker
data consistent with Alzheimer pathology (raised CSF total
tau level with reduced amyloid A42 fraction; Blennow and
Hampel, 2003; Hulstaert et al., 1999; Tapiola et al., 2009).
In total, 14 patients were included in the series: 9 had
pathologically confirmed Alzheimer’s disease (7 who came
to postmortem and 2 on cerebral biopsy) and 5 had CSF
biomarkers consistent with AD (these 5 patients were pre-
viously reported in Rohrer et al., 2010). Clinical notes and
neuropsychological data were reviewed, and the clinical
diagnosis at the time the patient was initially assessed and a
revised clinical diagnosis based on current descriptive cri-teria for PPA (Mesulam, 2001, 2003; Gorno-Tempini et al.,
2004, 2008) were recorded in each case. Neuropsycholog-
ical data were also recorded where available. Ethical ap-
proval for the study was obtained from the National Hos-
pital for Neurology and Neurosurgery Local Research
Ethics Committee. Written research consent was obtained
from all patients participating in the study.
2.1. Brain imaging analysis
All subjects had been scanned on a 1.5 T GE Signa unit
scanner (General Electric, Milwaukee, WI) with T1-
weighted volumetric images obtained with a 24-cm field of
view and 256  256 matrix to provide 124 contiguous
1.5-mm-thick slices in the coronal plane. Mean (standard
deviation) age at scan was 60.2 (6.2) years. A control group
of 23 age- and gender-matched cognitively normal subjects
(mean age 63.5 [7.3] years at time of scan) was used for
comparison. No subject had significant cerebrovascular dis-
ease or other secondary pathology on neuroimaging. Image
analysis was performed using the MIDAS software package
(Freeborough et al., 1997). A rapid, semiautomated tech-
nique of brain segmentation which involves interactive se-
lection of thresholds, followed by a series of erosions and
dilations was performed for each scan. This yielded a brain
region which was separated from surrounding CSF, skull,
and dura giving a baseline brain volume. Ventricles were
also segmented within MIDAS. Scans and associated brain
regions were initially transformed into standard space by
registration to the Montreal Neurological Institute (MNI)
Template (Mazziotta et al., 1995). Left and right hemi-
spheric regions were defined using the MNI average brain
which was split by dividing the whole volume along a line
coincident with the interhemispheric fissure. An intersection
of each individual’s brain region and the hemispheric re-
gions defined on the MNI template was generated to provide
a measure of brain volume in left and right hemispheres and
left/right volume ratios were also calculated. The 2 disease
groups and the healthy control group were compared statis-
tically based on contrasts between the group means using a
linear regression model in STATA10 (Stata Corporation,
College Station, TX).
We investigated changes in imaging patterns with sever-
ity using cortical reconstruction and thickness estimation
methods with the Freesurfer image analysis suite (surfer.
nmr.mgh.harvard.edu/) as previously described (Rohrer et
al., 2009). We used performance on the Graded Naming
Test (McKenna and Warrington, 1980, total number of
items equals 30) (i.e., degree of anomia) as a measure of
disease severity, splitting the group according to their score:
group 1 (less severe: 9 patients) scored  0 (mean 7.7,
standard deviation 9.2) and group 2 (more severe: 4 pa-
tients) were unable to score. One case (AD-PPA6) with
greater right than left hemisphere atrophy was not included
in this analysis; this atrophy profile might reflect either a
different disease phenotype or reversed hemisphere lan-
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potentially bias any group-level correlations between corti-
cal thickness and disease severity.
Effect size maps were generated based on the difference
in mean thickness in each of these severity subgroups and in
the whole group, comparing each to the controls and ex-
pressing the disease-control difference as a percentage of
the mean control group thickness.
3. Results
3.1. Clinical and neuropsychological features
Demographic and clinical data for patients are presented
in Table 1; neuropsychological data (where available) are
presented in Table 2. All patients had language impairment
as their primary presenting feature. This was usually diffi-
culty finding words although 1 patient complained of a
return of a childhood stutter shortly before the onset of
word-finding difficulties. Spontaneous speech was rela-
tively nonfluent and occasional phonemic errors were made
by all patients, with occasional emergence of neologistic
jargon errors. None of the patients was described as having
had apraxia of speech. All of the patients who came to
postmortem or had a cerebral biopsy had initially received a
diagnosis of PPA, PNFA, or language variant frontotempo-
ral lobar degeneration although prior to death the diagnosis
in 2 of these cases was changed to atypical language variant
of AD. The 5 patients with CSF biomarkers consistent with
AD were ascertained more recently and had been diagnosed
with LPA before CSF analysis. On review of the clinical
notes of the 7 patients who came to postmortem and the 2
patients with cerebral biopsy-proven AD, all would also
have met criteria for LPA based on their initial symptoms
and neurocognitive assessment. A family history of demen-
tia was present in only 2 cases: these patients each had a
single parent with a diagnosis of Alzheimer’s disease in the
eighth decade. Myoclonus was noted in 2 patients and 2
patients developed generalized seizures. One patient exhib-
ited axial rigidity late in the course of the disease; no other
features of parkinsonism or motor neuron disease were
present in this series. Behavioral impairment was unusual
early in the illness but aggression, anxiety, and irritability
were noted in some patients later in the course.
Although all patients had had an initial neurocognitive
assessment, for many patients formal neuropsychological
testing was only performed later in the illness (e.g., when
AD-PPA4 was tested, Mini Mental State Examination
[MMSE] score was 4/30 and he performed poorly across
multiple domains). Consistent with a diagnosis of LPA,
neuropsychological assessment showed severely impaired
digit span in all but 3 patients, who scored in the low (but
not defective) range. Naming was in the impaired range at
initial assessment in over half of the patients and became
impaired in all cases as the disease progressed, also consis-
tent with LPA. Single-word comprehension was intact in 9 mof 14 patients as has been described in LPA but impaired in
the more severely affected patients (intact in those with
MMSE 18 or above, impaired in those with an MMSE
below 17). None of the patients complained of episodic
memory impairment at presentation, however verbal mem-
ory was impaired in 8 of 11 patients tested while visual
memory was affected less frequently (5 of 14 patients).
Reading was affected in most patients and some were noted
to have phonological dyslexia. Limb apraxia and dyscalcu-
lia were noted in most patients, however visuospatial skills
were intact in all but 1 severely affected patient. Executive
dysfunction was also seen in most patients.
3.2. Pathological features
Six of the 7 patients who came to postmortem had severe
Alzheimer pathology with Braak stage VI, and Consortium
to Establish a Registry for Alzheimer’s Disease (CERAD)
frequent plaques (Table 1). For the seventh case, no staging
information was available but this case had been reported as
showing severe Alzheimer pathology with frequent plaques
and tangles. Four cases were also noted to have cerebral
amyloid angiopathy. The 2 patients who had cerebral biop-
sies were noted to have frequent amyloid plaques and neu-
rofibrillary tangles.
3.3. Neuroimaging features
Volumetric magnetic resonance imaging (MRI) data for
patients and controls are presented in Table 3. Whole brain
and hemisphere volumes were smaller in patients and there
was evidence of left/right hemispheric asymmetry at group
level and in all but 1 of the individual patients; 1 (right-
handed) patient showed reverse asymmetry. Asymmetry
became more marked with increasing disease duration (Fig.
1, R  0.55, p  0.04).
In the cortical thickness analysis versus healthy controls
Fig. 2), group 1 (with less severe disease) showed areas of
ortical thinning predominantly in the left hemisphere, most
arked in the inferior parietal and posterior superior tem-
oral lobes. Other areas involved in the left hemisphere
ere posterior cingulate, precuneus, medial temporal lobe,
nd prefrontal cortex. In the right hemisphere, only the
osterior cingulate and precuneus and a small area in the
edial temporal lobe were affected. In group 2 with more
evere anomia, cortical thinning remained asymmetrical but
as more extensive within both hemispheres. In the left
emisphere there was additional involvement of anterior
uperior and middle temporal lobe, posterior medial tempo-
al lobe, and inferior frontal lobe areas. In the right hemi-
phere there was involvement of areas similar to those
nitially involved in the left hemisphere, i.e., lateral parietal,
osterior superior temporal, posterior cingulate, precuneus,
edial temporal, and prefrontal cortices.
Table 1
Demographic, symptom, and pathology data
Patient Gender Age at
onset
Total
duration
First symptoms Other linguistic symptoms Neurological
and behavioural symptoms
CSF Tissue pathology
AD-PPA1 M 59 9.3 Word-finding difficulty Phonemic errors, later
comprehension problems
Myoclonus and seizures N/A Braak VI, CERAD frequent
plaques, Reagan high
AD-PPA2 F 54 8.1 Word-finding difficulty Phonemic errors, sentence
repetition impairment
Seizures N/A Braak VI, CERAD frequent
plaques, Reagan high.
Mild cerebral amyloid angiopathy
AD-PPA3 M 50 6.3 Word-finding difficulty Phonemic errors Myoclonus N/A Severe pathology – frequent
plaques and tangles. Extensive
amyloid angiopathy
AD-PPA4 M 62 5.2 Return of childhood
stutter
Word-finding difficulty,
phonemic and jargon errors
Nil other noted N/A Braak VI, CERAD frequent
plaques, Reagan high.
Severe cerebral amyloid angiopathy
AD-PPA5 F 66 9.7 Word-finding difficulty Phonemic errors, sentence
repetition impairment
Nil other noted N/A Braak VI, CERAD frequent
plaques, Reagan high.
Severe cerebral amyloid angiopathy
AD-PPA6 M 50 7.2 Word-finding difficulty Phonemic and jargon errors,
later comprehension
problems
Later aggressive behaviour N/A Braak VI, CERAD frequent
plaques, Reagan high
AD-PPA7 M 54 8.9 Word-finding difficulty Phonemic errors Later axial rigidity
Later aggressive behaviour
N/A Braak VI, CERAD frequent
plaques, Reagan high
AD-PPA8 F 50 N/A Word-finding difficulty Phonemic errors Anxiety N/A Cerebral biopsy: Frequent plaques
and tangles
AD-PPA9 M 48 N/A Word-finding difficulty Phonemic errors Nil other notes N/A Cerebral biopsy: Frequent plaques
and tangles
AD-PPA10 M 60 N/A Word-finding difficulty Phonemic errors Later anxiety, irritability
and disinhibition
tau  1200 ng/L;
A42 195 ng/L
N/A
AD-PPA11 M 53 N/A Word-finding difficulty Phonemic errors Irritability tau 1146 ng/L,
A42 250 ng/L
N/A
AD-PPA12 F 63 N/A Word-finding difficulty Phonemic errors Anxiety and apathy tau 1124 ng/L,
A42 299 ng/L
N/A
AD-PPA13 M 59 N/A Word-finding difficulty Phonemic errors Irritability, restlessness
and agitation
tau 986 ng/L,
A42 138 ng/L
N/A
AD-PPA14 M 58 N/A Word-finding difficulty Phonemic and jargon errors,
later comprehension
problems
Anxiety tau 986 ng/L,
A42 130 ng/L
N/A
Cases shown in bold represent patients with CSF data consistent with AD, other cases are pathologically confirmed cases.
Key: AD, Alzheimer’s disease; CERAD, Consortium to Establish a Registry for Alzheimer’s Disease; CSF, cerebrospinal fluid; F, female; M, male; PPA, primary progressive aphasia.
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Here we have described a series of 14 patients with PPA
in association with proven or probable AD pathology. The
key clinical features of the cases in this series were initial
presentation with word-finding difficulty, and relatively
nonfluent spontaneous speech with occasional phonemic
errors but without motor speech impairment. “Word-finding
difficulty”, like fluency, refers to a cluster of related deficits
(Rohrer et al., 2008): though often related to anomia, pa-
tients with conversational pauses but with relatively intact
naming may also present with a word-finding problem.
Reviewing the diagnoses in this series revealed that all cases
fulfilled (or would likely have fulfilled) descriptive criteria
for LPA (Gorno-Tempini et al., 2004, 2008). The neuropsy-
Table 3
Volumetric MRI data
Controls AD-PPA
umber of subjects 23 14
uration of disease at scan, years N/A 4.1 (1.0)
ge at scan, years 63.5 (7.3) 60.2 (6.2)
rain volume, mL 1160.1 (96.5) 1083.7 (109.1)a
Left hemisphere volume, mL 570.9 (46.7) 526.4 (57.0)a
Right hemisphere volume, mL 571.3 (46.9) 547.9 (50.6)
Left/right hemisphere ratio 1.00 (0.01) 0.96 (0.03)a
Mean (standard deviation) values are shown. AD, Alzheimer’s disease;
MRI, magnetic resonance imaging; N/A, not applicable; PPA, primary
progressive aphasia.
a p  0.05 AD-PPA significantly worse than controls.
Fig. 1. Asymmetry ratio (left/right hemisphere volumes) as a function ofTa
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apraxia, and phonological dyslexia were consistent with
LPA (Amici et al., 2006; Brambati et al., 2009). However,
verbal memory, although not a presenting feature in any of
the patients, was also affected in most cases. Although this
feature has not been emphasized in some previous studies of
LPA, in 1 previous series 5 of 6 patients were impaired on
verbal memory tasks (Gorno-Tempini et al., 2008). In con-
trast, visuospatial processing (a right hemisphere function)
was generally well preserved. Cross-sectional brain imaging
revealed asymmetrical left-sided atrophy predominantly af-
fecting the posterior superior temporal lobe and inferior
parietal lobe but also the posterior cingulate, precuneus, and
medial temporal lobe. These features corroborate previous
neuroanatomical findings in LPA (Gorno-Tempini et al.,
2004, 2008). In more severe disease there was evidence of
atrophy spread to the left frontal lobe, more anterior left
temporal lobe areas, as well as posterior superior temporal
lobe, inferior parietal lobe, and posterior cingulate areas
within the right hemisphere.
The nosology of patients with language impairment and
AD pathology remains controversial. Such patients have
been classified either as having the symptomatic description
of PPA (with an LPA phenotype in most cases) or having
the predictive clinicopathological description of an atypical
“language variant” within the AD spectrum. While there
should not be conflict between these 2 descriptions as they
are essentially at 2 different levels of classification, predict-
ing which patients with a PPA syndrome will have AD
pathology (particularly in the absence of a PIB-PET scan or
CSF markers) is nevertheless often challenging during life.
Table 4
Previously reported series of patients with a primary progressive aphasia
Series Cases
considered
Pathologically confirmed
AD, n
Migliaccio et al.,
2009a
Only LPA cases 1 and 4 with positive
PIB scan
ereira et al., 2009b Only SD cases 3
abinovici et al.,
2008a
All PPA cases 0 but 6 with positive
PIB-PET scan
orno-Tempini et al.,
2008a
Only LPA cases 0 but 4 with positive
PIB-PET scan
esulam et al., 2008 All PPA cases 11
osephs et al., 2008 All PPA cases 5
lladi et al., 2007b All PPA cases 19
nibb et al., 2006b All PPA cases 12
ertesz et al., 2005 PNFA and LPA
cases
8
ean (standard deviation) values are shown. AD, Alzheimer’s disease; LPA
ositron emission tomography; PIB, ; PNFA, progressive nonfluent aphasia;
a From same research group and cases may overlap in different series.
b From same research group and cases may overlap in different series. Nal. (2000), and Galton et al. (2000).The extent of involvement of other cognitive domains may
be helpful, however the present evidence suggests that the
presence and severity of extralinguistic impairments de-
pends on disease stage. Furthermore, the clinical salience of
these additional impairments is variable: in this series, a
number of patients that performed poorly on episodic mem-
ory tasks did not complain of amnestic symptoms, whereas
2 patients who came to postmortem exhibited widespread
cognitive impairment prompting a reformulation of the clin-
ical diagnosis as an atypical language variant of AD. We
would argue that the presenting syndrome at an early dis-
ease stage is likely to provide the more rational basis for
classifying language dysfunction associated with AD, par-
ticularly as language impairments are very common as “typ-
ical” AD advances. This distinction is clinically important,
as recognition of PPA features that predict AD pathology
could help direct the use of investigations such as CSF and
PIB-PET, and ultimately, the selection of patients for clin-
ical trials and disease-modifying therapies.
Previous series from 5 research groups have reported
PPA patients with either pathologically confirmed AD or a
positive PIB-PET scan showing amyloid deposition (Table
4; Alladi et al., 2007; Croot et al., 2000; Davies et al., 2005;
Galton et al., 2000; Gorno-Tempini et al., 2008; Josephs et
al., 2008; Kertesz et al., 2005; Knibb et al., 2006; Mesulam
et al., 2008; Migliaccio et al., 2009; Pereira et al., 2009;
Rabinovici et al., 2008). Prior to the first detailed descrip-
tion of LPA (Gorno-Tempini et al., 2004), patients with
both PNFA and SD were reported with AD pathology but
since that time LPA has been the clinical syndrome most
closely associated with AD pathology. In Rabinovici et al.
heimer pathology
iagnosis Male,
%
Age at
onset
Duration Age at
death
NA NA NA NA
66.7 NA NA NA
, 1 SD, 1 PNFA NA NA NA NA
25.0 NA NA NA
, 1 SD, 3 “mixed” 63.6 61.8 (10.8) NA 73.2 (7.0)
ent aphasia” (“1 or
may meet criteria for
enic PPA”)
60.0 69 (12) NA 77 (13)
FA, 2 SD, 5 “mixed”
ed” cases include 3
2 atypical SD with
logical deficits)
NA 65.7 (8.1) 7.4 (2.9) NA
nfluent”, 5 “fluent” NA NA NA NA
NA NA NA NA
enic/phonological aphasia; NA, not available; SD, semantic dementia; PET,
rimary progressive aphasia.
lier series which include AD-PPA cases are Davies et al. (2005); Croot etand Alz
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PNFA and 1 of 5 patients with SD had positive PIB-PET
scans; in Mesulam et al. (2008), 7 of 11 logopenic patients
ad AD pathology, compared with none of the 6 agram-
atic patients, 3 of 5 of the “mixed” patients, and the single
emantic patient. It is important to recognize that classifi-
ation of PPA phenotypes generally depends on syndromic
haracterization, and overlap between syndromes is fre-
uent, particularly with disease evolution (e.g., LPA over-
aps both with PNFA and SD). It is unclear whether older
eries of PPA cases included patients that would now be
escribed as having LPA, e.g., in Alladi et al. (2007) many
of the patients with PNFA were diagnosed before the initial
description of LPA. In that study, 5 of 7 patients with a
mixed aphasia (including LPA) patients had AD pathology,
compared with 2 of 20 with SD and 12 of 26 with PNFA.
Improved understanding of the specific disease phenotypes
has refined clinicopathological correlations in PPA, e.g.,
patients with motor speech deficits (e.g., apraxia of speech)
appear to show an association with FTLD-tau rather than
AD pathology (Josephs et al., 2006). For the clinical syn-
drome of SD there is an association chiefly with FTLD-TDP
rather than AD pathology (Alladi et al., 2007; Snowden et
al., 2007). The SD syndrome underpinned by AD may be
associated with asymmetrical temporal lobe atrophy fo-
cused on the left hippocampus and superior temporal lobe,
rather than the temporal pole and anteroinferior temporal
lobe as in classical SD caused by FTLD-TDP pathology
Fig. 2. Patterns of cortical thinning in the Alzheimer’s disease (AD)-pri
severity of anomia: group 1, less severe (A); group 2, most severe (B). For
Percentage thinning maps are shown; the colored bar represents percentage value(Chan et al., 2001; Pereira et al., 2009; Rohrer et al., 2009).
More marked superior temporal lobe atrophy has been as-
sociated with LPA in other studies (Gorno-Tempini et al.,
2004, 2008).
An outstanding neurobiological question concerns the
overlap of LPA/atypical language-presentation AD with
typical amnestic AD (and with other atypical variants of AD
such as posterior cortical atrophy). Neuropsychologically,
there are few data to compare amnestic-onset AD with
atypical language variants but studies of language impair-
ment in typical AD have shown that patients can be
logopenic with an early anomia, and that phonological and
semantic impairments also occur (Adlam et al., 2006; Blair
et al., 2007; Chertkow et al., 2008; Garrard et al., 2001;
Harasty et al., 1999, 2001; Peters et al., 2009; Taler and
Phillips, 2008). Motor speech impairment (apraxia of
speech) has been reported only rarely in association with
AD (Gerstner et al., 2007). From an anatomical perspective,
LPA is associated with asymmetrical atrophy compared
with the relatively symmetrical atrophy of amnestic AD
(Gorno-Tempini et al., 2004). However, certain key areas of
atrophy or cortical thinning are implicated in both LPA-AD
and typical AD, i.e., the temporo-parietal junction, the pre-
cuneus, posterior cingulate, and the medial temporal lobe
(Scahill et al., 2002). One recent study has shown an overlap
of patterns of atrophy in these areas in early onset amnestic
AD, posterior cortical atrophy, and LPA (Migliaccio et al.,
2009). The present study has certain limitations, including
ogressive aphasia (PPA) groups versus healthy controls, categorized by
misphere, the top panels are lateral views, the bottom panels medial views.mary pr
each hes.
751J.D. Rohrer et al. / Neurobiology of Aging 33 (2012) 744–752relatively small patient numbers, retrospective ascertain-
ment, and most importantly, lack of uniform histopatholog-
ical confirmation. Taking these caveats into account, the
present evidence in conjunction with previous work sug-
gests that the LPA syndrome might be regarded, very
broadly, as a “uni-hemispheric” presentation of AD. Further
detailed longitudinal prospective studies comparing amnes-
tic and language presentations of AD are needed to eluci-
date the pathophysiological mechanisms that instigate and
sustain neuropsychological and anatomical asymmetry.
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